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S U M M A R Y
In this article we describe the key role of tuberculosis (TB) treatment, the challenges (mainly the
emergence of drug resistance), and the opportunities represented by the correct approach to drug
dosage, based on the existing control and elimination strategies. In this context, the role and contribution
of therapeutic drug monitoring (TDM) is discussed in detail. Treatment success in multidrug-resistant
(MDR) TB cases is low (62%, with 7% failing or relapsing and 9% dying) and in extensively drug-resistant
(XDR) TB cases is even lower (40%, with 22% failing or relapsing and 15% dying). The treatment of drug-
resistant TB is also more expensive (exceeding s50 000 for MDR-TB and s160 000 for XDR-TB) and more
toxic if compared to that prescribed for drug-susceptible TB. Appropriate dosing of ﬁrst- and second-line
anti-TB drugs can improve the patient’s prognosis and lower treatment costs. TDM is based on the
measurement of drug concentrations in blood samples collected at appropriate times and subsequent
dose adjustment according to the target concentration. The ‘dried blood spot’ technique offers additional
advantages, providing the rationale for discussions regarding a possible future network of selected,
quality-controlled reference laboratories for the processing of dried blood spots of difﬁcult-to-treat
patients from reference TB clinics around the world.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
In this article we describe the key role of tuberculosis (TB)
treatment, the challenges (mainly the emergence of drug resis-
tance), and the opportunities represented by the correct approach
to drug dosage based on the existing strategies of the World Health
Organization (WHO). In this context, the role and contribution of
therapeutic drug monitoring (TDM) is discussed in detail.
The European Respiratory Society (ERS) and the WHO devel-
oped the Framework for Tuberculosis Elimination in Low-
incidence Countries1 in Rome, Italy in July 2014; this is focused
on the concept of pre-elimination (deﬁned as <10 TB cases per
million population) and TB elimination (deﬁned as <1 TB case per
million population).2–5 The vision of a TB-free world (zero death,
disease, and suffering due to TB) is consistent with the new* Corresponding author. Tel.: +39 0331829404.
E-mail address: giovannibattista.migliori@fsm.it (G.B. Migliori).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).post-2015 WHO global TB strategy, which has been named the ‘End
TB Strategy’.6 The overall goal of the strategy is to end the global TB
epidemic, with corresponding 2035 targets of a 95% reduction in TB
deaths and a 90% reduction in TB incidence (both compared with
2015). The strategy also includes a target of zero catastrophic costs
for TB-affected families by 2020.
To reach this goal, a set of coherent additional actions needs to
be implemented in order to improve access to high-quality TB
services (prevention, diagnostic, and treatment), especially for
vulnerable groups. Also, efforts should be made to address the
underlying determinants that put people at risk of TB.
A recent ERS/WHO survey demonstrated that several actions or
‘areas’ relevant to TB elimination, particularly in the clinical ﬁeld,
are not fully covered in Europe;5 thus, any information that sheds
light on the best clinical and public health practices contributing to
improved clinical management will favour TB elimination.
TDM is a tool that may be of help in optimizing TB treatment
and is thereby likely to support TB elimination strategies. The aimciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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cases and to present a TDM strategy that could be implemented in
a programmatic setting with the scope of controlling and
eliminating TB.
2. Methods
By exploring the recent literature we sought to detect TB sub-
populations with the highest burden of disease or consuming the
greatest health care budget. We subsequently evaluated whether
TDM could be of help to solve the problems in this TB population
and how it could be implemented in a programmatic treatment
setting.
3. Results
A challenge to the attainment of TB elimination is represented by
multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.
In 2013, the WHO estimated that there were 9 million TB incident
cases globally, equivalent to 126 cases per 100 000 population;
out of these, an estimated 480 000 cases were affected by MDR
Mycobacterium tuberculosis strains.6 Among newly diagnosed
patients, approximately 3.5% were infected with MDR-TB strains.
Of particular worry, however, is that the prevalence of MDR-TB
among new cases in some of the Former Soviet Union countries
exceeds 30%.6–9XDR-TB has been identiﬁed in 100 countries, and the
average proportion of MDR-TB cases with an XDR-TB pattern is
9.0%.6 Furthermore, an additional problem is the emergence and
spread of mycobacterial strains with ‘total drug resistance’,10–12 a
term currently not recognized by the WHO and replaced with ‘drug
resistance beyond XDR’.13
In the largest MDR-TB cohort ever analyzed,14 the proportion of
cases treated successfully was 62%, with 7% failing or relapsing, 9%
dying, and 17% defaulting. In the XDR-TB subgroup, treatment
outcomes were even worse: 40% achieved treatment success and
22% failed treatment or relapsed, 15% died, and 16% defaulted.15
The treatment of drug-resistant TB is more expensive and more
toxic compared to that prescribed for drug-susceptible TB, and
currently takes up to 2 years of therapy.16 The cost per patient to
treat MDR-TB cases is incredibly high,17,18 and in spite of
international public health efforts, the treatment outcome is not
very promising.13–15Diel et al. showed that direct treatment-relatedTable 1
Implementation of TDM (therapeutic drug monitoring)
Procedure 
Analytical
procedure
Assay that combines ﬁrst-line or second-line drugs in a sing
Select local or referral laboratory to analyze patient sample
In the case of DBS, verify appropriate blood collection protoc
materials to be used with the laboratory
Case selection Priority to:
 Patients failing to convert within 2 months of standardize
treatment
 Patients showing adverse drug reactions
 Patients with multiple risk factors for low drug exposure
diagnosis: HIV-positive, diabetes type 2, gastrointestinal tra
problems, severely ill patients
Sample collection Venipuncture used to collect plasma; ﬁnger prick used to c
DBS
Time points should be properly selected to enable accurate
optimization of the dose
Dose adjustment Dose adjustment should be based on both drug exposure a
MIC of the Mycobacterium tuberculosis strain in order to atta
optimal PK/PD target
Perform follow-up at 1–2 weeks after dose adjustment to e
that the target drug concentrations are reached
TDM, therapeutic drug monitoring; DBS, dried blood spot; MIC, minimum inhibitory ccosts for MDR-TB patients can amount tos52 259in Germany.19The
same group demonstrated that the average cost to treat an XDR-TB
case in Europe largely exceeds s160 000.
One of the most important causes of the emergence of drug
resistance is the pharmacokinetic variability of anti-TB drugs
resulting in the exposure of M. tuberculosis strains to sub-
therapeutic drug concentrations.20,21 This also applies for patients
on treatment for MDR-TB. A recent study showed that patients
without baseline resistance acquired ﬂuoroquinolone resistance
and second-line injectable drug resistance, with 8.9% acquiring
extensively drug-resistant TB.22 Appropriate dosing of the few and
less effective antibacterial options remaining could dramatically
inﬂuence the prognosis. TDM is based on the measurement of drug
concentrations in blood samples collected at appropriate times and
subsequent dose adjustment according to the target concentra-
tion.23–25 Based on pharmacokinetic and pharmacodynamic
principles it can indirectly assess the effect of the drugs on the
bacterial target.26 Details of the pharmacokinetic and pharmaco-
dynamic targets for second-line drugs have been published
elsewhere.27
In addition to the pharmacokinetic variability of the anti-TB
drugs, an inadequate dose or dosing frequency and non-adherence
to the prescribed regimen are also deemed to be responsible for the
development of drug-resistant TB.28–30 Although the recent
introduction of new diagnostics has allowed the rapid detection
of drug resistance,31 TDM has not been implemented properly for
the management of TB therapy,32 thereby providing opportunities
to adjust the dosing in the case of a low serum concentration.32–34
Furthermore, TDM can indirectly change the prognosis when
less than ﬁve effective drugs are available. It can help prevent the
development of further resistance as a result of low serum
exposure; moreover, the detection of high blood levels can allow
adjustment of the dosage and thus reduce the occurrence of
adverse events that could decrease patient adherence.
Additional information on the implementation of TDM is
reported in Table 1.
Conventional TDM is characterized by the determination of
drug concentrations in plasma or serum. Many assays describing
the optimal analytical procedure can be found in the current
literature. However, an assay enabling the measurement of
multiple drugs in a single sample is preferrable.35 Nevertheless,
many laboratories have single drug assays that require a trainedComments
le run Combination assays reduce the sample volume required
TDM saves costs
s Selection of a certiﬁed laboratory is necessary to assure accurate
analytical TDM results
ol and Deviations produce erratic results
d
 at
ct
A targeted approach reduces the number of patients for whom TDM
has to be performed
ollect DBS may be preferred in the outpatient setting or in the case where
samples are sent to a referral laboratory to save transportation costs
Optimized sampling may be preferred over ‘trough and peak’
nd the
in the
This strategy avoids unnecessary dose adjustment in patients with
low drug exposure and a very susceptible M. tuberculosis strain
nsure Not every dose increase results in increased drug exposure; switch
route of administration of the drug to IV when available
oncentration; PK/PD, pharmacokinetic/pharmacodynamic; IV, intravenous.
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this procedure not too invasive for the patient.
An easier and less expensive approach is the use of the ‘dried
blood spot’ (DBS; Figure 1).36 The DBS, used successfully in otherFigure 1. Procedure to obtain a dried blood spot (DBS). Images courtesy of Remco
Koster. (a) Use a commercially available DBS card; ensure that the card type
selected is one that your laboratory is able to analyze. (b) Pre-clean and warm the
ﬁnger, prick the ﬁnger, and discard the ﬁrst drop of blood. (c) Let the drop of blood
‘fall’ onto the DBS card; do not touch or smear the blood onto the DBS card. (d) Let
the DBS card dry in air for the speciﬁed time period, store it in a zip lock bag with
desiccant, and send to the laboratory.infectious disease ﬁelds (e.g., human cytomegalovirus), is an
innovative methodological approach, allowing smaller blood
volume collection and easier sampling, storage, and transporta-
tion. The latter features can be particularly helpful in low-income
countries. The DBS has already been developed and evaluated
clinically for important second-line drugs including moxiﬂoxa-
cin37 and linezolid,38 and also for clarithromycin.39
4. Discussion
Although TDM for second-line drugs seems reasonable to
optimize the treatment of MDR-TB, a lack of data from prospective
studies, logistical issues, and costs are still hindering its implemen-
tation and scale-up, even in high-income countries. Only a few
laboratories perform the technique and interpret TDM results.23,40
However, in Europe a group of scientists from Nijmegen and
Groningen, the Netherlands, have set up a proﬁciency testing
programme aimed at improving the overall quality of TDM.
The cost of TDM, within country and laboratory variability, is
estimated to be US$560 to test four drugs at two time points, but will
likely fall with the implementation of analytical methods that can
measure all drugs using a single procedure.35 Further costs are
related to the collection and shipment of the samples to the referral
laboratory.23,41 Despite this ﬁnancial imbalance, a comprehensive
analysis cannot take into account the costs following the occurrence
of adverse events, unsuccessful outcomes, and the transmission of
drug-resistant mycobacteria in the population.17–19
A network of national reference laboratories similar to that
adopted for the surveillance of drug-resistance42 could also be
considered for TDM. DBS are easier and cheaper to send than
infectious materials (M. tuberculosis strains), so the ordinary mail
system could be used at really low cost. Selected, quality-
controlled reference laboratories could receive the DBS of
difﬁcult-to-treat patients from reference MDR-TB clinics.
The reasons for its implementation, as previously discussed
(including the savings related to the preservation of the safety and
efﬁcacy of current anti-TB regimens for drug-resistant cases),
appear to open the door to the future involvement of low-income
countries, even if further scientiﬁc evidence is needed.16,43,44
A health technology assessment may represent the most rapid
way to obtain a clear response in an era in which the sustainability
of healthcare systems (including those in high-income countries)
needs to be demonstrated.
On this basis, we support the rationale of gaining further
evidence not only on the clinical use of TDM, but also on the
possible development of a well-organized public health vision,
allowing more and more patients to beneﬁt from this test.
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